Login to Your Account



OncoGenex Gains 75 Percent on OGX-011 Phase II Prostate Data

By Trista Morrison


Thursday, December 4, 2008
Shares of OncoGenex Pharmaceuticals Inc. soared 75.6 percent on Wednesday thanks to positive survival data from a Phase II trial of lead compound OGX-011 in the first-line treatment of hormone refractory prostate cancer (HRPC). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription